Keyword Search
Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: interim analysis returned 9 record(s)
|
|
Tuesday, 08/01/2017
|
A Two-Stage Design for Phase III Trials with Population Selection
Wen Li, Merck & Co. Inc.
8:50 AM
|
Decision of Performing Interim Analysis for Comparative Clinical Trials
Kyongsun Pak, Kitasato University; Susanna Jacobus, Dana Farber Cancer Institute; Hajime Uno, Dana Farber Cancer Institute
10:35 AM
|
Determination of Interim Go/No-Go Criteria with Simulations of Longitudinal Continuous Data in a Phase 2 Clinical Trial of a Neurodegenerative Disorder
Weining Z Robieson, AbbVie Inc.; Greg Cicconetti, Abbvie; Deli Wang, AbbVie, Inc.
11:05 AM
|
Strategies in Designing Interim Analyzes Under Discrete Random-Effects Model in a Multiregional Trial
Hsiao-Hui Tsou, National Health Research Institutes; Chi-Tian Chen, National Health Research Institutes; K. K. Gordon Lan, Janssen Pharmaceutical Companies of Johnson & Johnson; Chin-Fu Hsiao, National Health Research Institutes
11:35 AM
|
Extensions of Adaptive Sample Size Re-Estimation Methods to the Negative Binomial Setting
Mikhail Peter Salganik, Pfizer Worldwide Research & Development, Pfizer, Inc ; Sandeep Menon, Pfizer, Inc; Abigail Sloan, Harvard T.H. Chan School of Public Health
2:45 PM
|
Implementation of Promising Zone Methodology in a Ph 3 Trial in AML (VALOR)
Jennifer Smith, Sunesis
3:25 PM
|
|
|
